北京万东医疗科技股份有限公司 关于公司及子公司使用闲置募集资金 及自有资金进行现金管理的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导 性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法 律责任。 重要内容提示： 产品种类：银行理财 本次现金管理总额：募集资金 1 亿元、自有资金 1 亿元 履行的审议程序：2025年 3月 20日召开的第十届董事会第六次会议、 第十届监事会第六次会议及 2025 年 4 月 16 日召开的 2024 年年度股东大会 审议批准《关于使用部分暂时闲置募集资金及自有资金进行现金管理的议 案》。 证券代码：600055 证券简称：万东医疗 编号：临 2025-034 一、情况概述 （一）现金管理目的 北京万东医疗科技股份有限公司（以下简称"公司"）及子公司为提 高募集资金和自有资金效率，合理利用部分闲置募集资金及自有资金，在 确保不影响募集资金项目建设和使用、募集资金和自有资金安全的情况下， 增加公司的收益，为公司及股东获取更多回报。 （二）现金管理金额 本次现金管理总金额为：公司使用募集资金 1 亿元,自有资金 1 亿元。 （三）资金来源及相关 ...

Group 1 - The ASEAN Secretary-General Roundtable held in Beijing aimed to explore new cooperation opportunities among 33 prominent companies and industry leaders from China and ASEAN in sectors such as finance, technology, and pharmaceuticals [1] - Since the implementation of the Regional Comprehensive Economic Partnership (RCEP), trade and cultural exchanges between Beijing and ASEAN countries have intensified, with Beijing companies accelerating their investment in ASEAN markets [1] - The event was a follow-up to a friendly cooperation agreement signed between the Beijing Trade Promotion Council and the ASEAN Economic and Trade Promotion Association, aiming to deepen practical cooperation among enterprises [1] Group 2 - Chinese companies participating in the roundtable primarily focused on technology and biomedicine, reflecting a strong interest in the potential of the ASEAN market, particularly among private enterprises [1] - The Vice President of Public Affairs at Beijing Quantum Song Group highlighted the company's recent acquisition in the trendy toy industry and its expansion into Southeast Asia, indicating a timely opportunity for policy and business resource connections [2] - The ASEAN Secretary-General noted that the RCEP has broadened the scope of cooperation between China and ASEAN, creating more opportunities in professional services, e-commerce, and investment, thus providing greater certainty and transparency for businesses and investors [2]

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Wandong Medical, which has a current stock price of 17.8 yuan and a rolling PE ratio of 78.64 times, significantly higher than the industry average of 54.55 times [1][2] - As of March 31, 2025, Wandong Medical has 30,385 shareholders, an increase of 397 from the previous period, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] - The company specializes in the research, production, sales, and after-sales service of large medical imaging equipment, with its main product being medical device sales [1] Group 2 - The "Wandong WDL Wide-area Deep Learning Platform" has been implemented in several leading hospitals, including Peking University Jishuitan Hospital and Huazhong University of Science and Technology Tongji Medical College Hospital, and has received the "Craftsmanship Technology Award" for its accessibility [1] - In the first quarter of 2025, the company reported a revenue of 373 million yuan, a year-on-year increase of 21.00%, and a net profit of 35.05 million yuan, reflecting a year-on-year growth of 5.40%, with a gross profit margin of 37.75% [1] - The company ranks 99th in the medical device industry based on PE ratio, with the industry median at 37.54 times [1][2]

Investment Rating - The industry investment rating is "Outperform the Market" [2][45] Core Insights - The total bidding amount for medical devices in June 2025 reached 12.618 billion yuan, representing a year-on-year growth of 30% and a total of 83.817 billion yuan for the first half of 2025, with an overall year-on-year increase of 64% [3][9][10] Summary by Sections Medical Device Bidding Overview - The medical device bidding amount in June 2025 was 12.618 billion yuan, showing a year-on-year increase of 30% and a quarter-on-quarter decrease of 6% [9] - The cumulative bidding amount for the first half of 2025 was 83.817 billion yuan, with a year-on-year growth of 64% [10] Domestic Brands - Mindray Medical's bidding amount in June 2025 was 623 million yuan, up 15% year-on-year, with a total of 4.258 billion yuan for the first half of 2025, reflecting a 64% increase [16][18] - United Imaging's June 2025 bidding amount was 769 million yuan, a 35% year-on-year increase, totaling 4.841 billion yuan for the first half of 2025, up 53% [13][14] - Aohua Endoscopy's June 2025 bidding amount was 27 million yuan, down 46% year-on-year, with a total of 235 million yuan for the first half of 2025, up 57% [19][20] - Kaili Medical's June 2025 bidding amount was 102 million yuan, a 73% year-on-year increase, totaling 642 million yuan for the first half of 2025, up 115% [22][23] - Shanwaishan's June 2025 bidding amount was 30 million yuan, a 222% year-on-year increase, totaling 186 million yuan for the first half of 2025, up 211% [25][26] - Wandong Medical's June 2025 bidding amount was 222 million yuan, a 416% year-on-year increase, totaling 728 million yuan for the first half of 2025, up 107% [28][29] Imported Brands - Philips' June 2025 bidding amount was 658 million yuan, down 4% year-on-year, with a total of 4.570 billion yuan for the first half of 2025, up 61% [31][32] - Siemens' June 2025 bidding amount was 978 million yuan, a 48% year-on-year increase, totaling 6.074 billion yuan for the first half of 2025, up 60% [34][35] - GE's June 2025 bidding amount was 1.447 billion yuan, a 49% year-on-year increase, totaling 6.736 billion yuan for the first half of 2025, up 56% [37][38]

北京万东医疗科技股份有限公司关于 2022 年员工持股计划股票出售完毕暨终止的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导 性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责 任。 北京万东医疗科技股份有限公司（以下简称"公司"）2022年员工持 股计划所持有的公司股票已全部出售完毕。根据《关于上市公司实施员工 持股计划试点的指导意见》《上海证券交易所上市公司自律监管指引第1号 ——规范运作》等规定，现将相关情况公告如下： 证券代码：600055 证券简称：万东医疗 编号：临 2025-033 北京万东医疗科技股份有限公司 董事会 2025 年 6 月 28 日 截至本公告披露日，公司2022年员工持股计划所持有的公司股票已经 通过集中竞价交易方式全部出售完毕，员工持股计划管理委员会将根据《万 东医疗2022年员工持股计划管理办法》的相关规定及持有人会议的授权开 展清算工作，待相关工作完成后，本员工持股计划终止。 特此公告。 一、员工持股计划的基本情况 公司于2022年4月21日召开第九届董事会第六次会议和第九届监事会 第六次会议、2022年5月13日召开2021年年度股东 ...

证券代码：600055 证券简称：万东医疗 编号：临 2025-032 北京万东医疗科技股份有限公司 关于公司及子公司使用闲置募集资金 及自有资金进行现金管理的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导 性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法 律责任。 重要内容提示： 产品种类：银行理财 本次现金管理总额：募集资金 0.5 亿元、自有资金 1.5 亿元 履行的审议程序：2025年 3月 20日召开的第十届董事会第六次会议、 第十届监事会第六次会议及 2025 年 4 月 16 日召开的 2024 年年度股东大会 审议批准《关于使用部分暂时闲置募集资金及自有资金进行现金管理的议 案》。 一、情况概述 （一）现金管理目的 限公司欧元/美元固定日观察区间型结构性存款，本存款所指挂钩标的定盘 价格为彭博页面"BFIX"在东京时间下午 3 点显示的挂钩标的中间价，取 值小数点后五位，本产品协议项下挂钩标的为【欧元兑美元即期汇率】。 2025 年 6 月 12 日，公司子公司万里云医疗信息科技（北京）有限公司 （以下简称"万里云"）以 2,000 万元自有资金购买了招 ...

Core Insights - The medical equipment industry is facing significant price reductions due to centralized procurement initiatives, with many devices seeing price drops exceeding 50% [7][9][12] - The shift towards "price for volume" in procurement is leading to a restructuring of the market, impacting both domestic manufacturers and international competitors [2][5][12] - The competitive landscape is changing, with leading companies benefiting from cash flow while smaller firms may struggle to survive [12][18] Group 1: Price Reductions and Market Dynamics - Centralized procurement in regions like Sichuan, Henan, and Xinjiang is drastically lowering prices for medical equipment, with some devices like 1.5T MRI machines dropping to around 500,000 yuan from 2 million yuan [2][9] - Over 30% of procurement projects have seen price drops exceeding 50%, with 27% experiencing reductions over 70% [7][9] - The average price drop for ultrasound devices is significant, with major players like Mindray securing large orders despite steep price reductions [9][10] Group 2: Impact on Manufacturers - Domestic manufacturers are facing challenges as they attempt to compete with international firms, with many experiencing squeezed profit margins due to aggressive pricing strategies [5][12] - High-end equipment is less affected by price drops, allowing manufacturers in this segment to maintain profitability while increasing sales volume [9][12] - The procurement process is favoring established companies with strong distribution channels, while smaller firms may need to innovate or seek acquisition to remain competitive [12][18] Group 3: Future Trends and Considerations - The focus of procurement policies is shifting from merely achieving low prices to balancing cost with meeting clinical needs, which may create opportunities for innovative products [18][19] - There is a growing recognition of the need for a fair competitive environment that allows for new entrants and maintains market vitality [18][19] - The integration of AI in imaging devices is becoming a standard, potentially impacting pricing and market dynamics for software solutions [13][19]

Group 1 - The core viewpoint of the articles highlights the strategic shift of Beijing Wandong Medical Technology Co., Ltd. (Midea Wandong) from selling DR equipment to providing comprehensive orthopedic solutions, aiming to support private medical institutions in overcoming challenges in the healthcare industry [1][2] - Midea Wandong has served over 30,000 medical institutions annually and has provided more than 100,000 medical imaging devices globally [2] - The company achieved a revenue of 1.524 billion yuan in 2024, representing a year-on-year growth of 23.26% [2] Group 2 - The private hospital sector in China has seen its proportion rise to nearly 70%, yet it only accounts for about 20% of outpatient volume, indicating a disparity in service capacity compared to public hospitals [1] - Midea Wandong aims to leverage its brand advantages to actively participate in ecosystem construction, addressing the challenges faced by private medical institutions and enhancing their capabilities [1] - The company emphasizes the importance of integrating innovative technologies with the development of disciplines and applications in private healthcare, which is a pressing issue that needs to be addressed [1]

Investment Rating - The industry investment rating is "Outperform the Market" [4][46]. Core Viewpoints - The total bid amount for medical devices in May 2025 reached 13.43 billion yuan, representing a year-on-year increase of 69% and a cumulative total of 71.45 billion yuan from January to May, with a year-on-year growth of 72% [5][11]. - Domestic medical device companies showed significant growth, with notable increases in ultrasound and endoscope categories [6][20][23]. - Imported brands also experienced rapid growth, particularly in CT equipment, which saw a year-on-year increase of 282% for Siemens in May [7][35]. Summary by Sections Medical Device Procurement Overview - The total bid amount for May 2025 was 13.43 billion yuan, a 69% increase year-on-year, while the cumulative total for January to May was 71.45 billion yuan, up 72% year-on-year [11][12]. Domestic Brands - Major domestic companies like Mindray, United Imaging, and Aohua Endoscopy reported substantial growth in bid amounts, with Mindray achieving 8.19 billion yuan in May, a 56% increase year-on-year [17][18]. - Aohua Endoscopy's bid amount in May was 0.35 billion yuan, reflecting a remarkable 242% year-on-year growth [20][21]. - Other companies like KAILI and Shanfeng also reported significant increases, with KAILI's bid amount growing by 137% in May [23][24]. Imported Brands - Philips reported a bid amount of 6.11 billion yuan in May, a 62% increase year-on-year, while Siemens achieved 11.57 billion yuan, marking a 112% increase [32][35]. - GE's bid amount reached 9.54 billion yuan in May, reflecting a 47% year-on-year growth [38][39]. - The CT segment for Siemens saw a staggering 282% increase in May, highlighting the strong demand for advanced imaging technologies [35][36].

Core Points - The board of directors of Beijing Wandong Medical Technology Co., Ltd. held its ninth meeting of the tenth session on June 9, 2025, via telecommunication voting [1][2] - The meeting was attended by all 8 directors, and the resolutions made were in compliance with the Company Law and the Articles of Association [1] - The board approved a proposal to adjust the members of certain specialized committees to enhance the corporate governance structure [1][2] Committee Adjustments - After the adjustments, Mr. Ma Chibing is a member of both the Strategic Committee and the Compensation and Assessment Committee, serving as the convener of the Strategic Committee [2] - The composition of the Strategic Committee includes Mr. Ma Chibing, Mr. Song Jinsong, Ms. Zhong Zheng, and Mr. Liu Xiao, with Mr. Ma as the convener [2] - The Compensation and Assessment Committee consists of independent directors Mr. Zhao Jun and Ms. Sun Yan, along with Mr. Ma Chibing, with Mr. Zhao as the convener [2] - The voting results for the proposal were unanimous, with 8 votes in favor, 0 against, and 0 abstentions [2]